MedTrace Logo

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

NCT04720534 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2026-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.

Conditions

Interventions

DRUG

ARO-APOC3

2 doses of ARO-APOC3 by subcutaneous (sc) injection

DRUG

Placebo

calculated volume to match active treatment by sc injection

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2023-03-09
Completion
2023-08-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Hungary
  • Netherlands
  • New Zealand
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04720534 on ClinicalTrials.gov